Department of Otorhinolaryngology/Head and Neck Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Shizuoka, Japan.
Yamahoshi ENT Clinic, 1-4-6 Shitoro, Nishi-ku, Hamamatsu, 432-8069, Shizuoka, Japan.
Int J Clin Oncol. 2020 Mar;25(3):432-438. doi: 10.1007/s10147-019-01531-w. Epub 2019 Aug 23.
There are no universally accepted treatment recommendations for elderly patients with head and neck carcinomas. This study investigated whether radical treatment in elderly patients resulted in better survival compared with palliative treatment.
We retrospectively reviewed the medical records of 724 patients aged > 60 years who underwent treatment for primary head and neck carcinomas at Hamamatsu University Hospital. We evaluated the impact of the following: age, sex, the clinical stage, smoking history, alcohol use history, primary tumor site, performance status, and Osaka Head and Neck Comorbidity Index score on overall survival using a Cox proportional hazards model.
The 5-year overall survival rate was significantly greater for the 646 patients initially treated with radical (curative) therapy than for the 78 patients treated with palliative therapy (p < 0.01). Patients who received palliative treatment in all age groups were more likely to die than were those in the radical treatment group, after controlling for age, sex, and clinical stage of the cancer. Information on the survival status of patients was obtained after a mean follow-up period of 46 months (range 6-205 months).
In the absence of contraindications associated with comorbidities, radical treatment protocols should be recommended for elderly patients with head and neck carcinomas because they confer better survival.
对于老年头颈部癌患者,目前尚无普遍接受的治疗建议。本研究旨在探讨老年患者的根治性治疗是否比姑息性治疗更能提高生存率。
我们回顾性分析了在滨松大学医院接受原发性头颈部癌治疗的 724 例年龄>60 岁患者的病历。我们使用 Cox 比例风险模型评估了以下因素对总生存期的影响:年龄、性别、临床分期、吸烟史、饮酒史、原发肿瘤部位、体能状态和大阪头颈部合并症指数评分。
646 例初始接受根治性(治愈性)治疗的患者 5 年总生存率显著高于 78 例接受姑息性治疗的患者(p<0.01)。在控制了年龄、性别和癌症的临床分期后,所有年龄组接受姑息性治疗的患者比接受根治性治疗的患者更有可能死亡。在平均随访 46 个月(范围 6-205 个月)后获得了患者生存状态的信息。
在无合并症相关禁忌证的情况下,应推荐老年头颈部癌患者采用根治性治疗方案,因为这可以提高生存率。